ml9

ML-9 (free base) suppresses MLCK, PKA, and PKC activity (Ki: 4, 32, and 54 μM, respectively). ML-9 (free base) is a selective and effective inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK), and stromal interaction molecule 1 (STIM1) acti

ML-9 suppresses MLCK, PKA, and PKC activity with Ki values of 4, 32, and 54 μM, respectively. ML-9 is a selective and effective inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK), and stromal interaction molecule 1 (STIM1) activity. ML-9 causes autophagy by stimulating autophagosome formation and inhibiting their degradation.

ML901 is an antimalarial compound with an IC50 value of 2 nM against Plasmodium parasites. It functions by selectively inhibiting Plasmodium falciparum tyrosine tRNA synthetase (PfYRS) through a "reaction hijacking" mechanism. ML901 demonstrates full life-cycle killing activity in mouse models of malaria and can be used for studying Plasmodium infections.

ML-93 is an orally active SAE inhibitor with an IC50 value of 0.4 μM. It effectively inhibits the SUMOylation pathway in HCT116 cells and demonstrates potent antitumor activity in HCT116 colorectal cancer xenograft models. ML-93 is applicable in colorectal cancer research.